◀ Back to MMP9

ARCN1 — MMP9

Text-mined interactions from Literome

Baraldo et al., Chest 2007 (Disease Progression...) : In all compartments, MMP-2 expression was increased both in smokers with severe COPD and in smokers with mild/moderate COPD compared to control smokers and nonsmokers ( p < 0.05 for all comparisons )
Muroski et al., Curr Pharm Biotechnol 2008 (Multiple Sclerosis...) : These observations lead to the hypothesis that MMP-9 is a potential drug target for both COPD and MS and further development of highly potent and specific MMP-9 inhibitors is warranted
Gao et al., Zhongguo Zhong Xi Yi Jie He Za Zhi 2012 (Pulmonary Disease, Chronic Obstructive) : Compared with the normal control group, the serum MMP-9 level obviously increased in the COPD of CDS group ( P < 0.05 ). The MMP-1 mRNA expression level in the bone tissue of the COPD of CDS group and the COPD model group also obviously increased ( P < 0.01, P < 0.05 ). The MMP-1 mRNA expression level was obviously higher in the COPD of CDS group than in the COPD model group ( P < 0.01 ). There was no statistical difference in the serum TNF-alpha level among the three groups ( P > 0.05 )
Simpson et al., Mediators Inflamm 2013 (Inflammation...) : TLR2 levels were increased with ageing, while sputum neutrophils and total sputum MMP-9 levels increased with age, previous smoking, and COPD